169 related articles for article (PubMed ID: 32594568)
21. The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy.
Gouas D; Shi H; Hainaut P
Cancer Lett; 2009 Dec; 286(1):29-37. PubMed ID: 19376640
[TBL] [Abstract][Full Text] [Related]
22. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.
Liao W; Yang H; Xu H; Wang Y; Ge P; Ren J; Xu W; Lu X; Sang X; Zhong S; Zhang H; Mao Y
Oncotarget; 2016 Jun; 7(26):40481-40490. PubMed ID: 27248174
[TBL] [Abstract][Full Text] [Related]
23. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
Ding X; He M; Chan AWH; Song QX; Sze SC; Chen H; Man MKH; Man K; Chan SL; Lai PBS; Wang X; Wong N
Gastroenterology; 2020 May; ():. PubMed ID: 32428506
[TBL] [Abstract][Full Text] [Related]
24. TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma.
Ye S; Zhao XY; Hu XG; Li T; Xu QR; Yang HM; Huang DS; Yang L
Oncol Rep; 2017 Apr; 37(4):2215-2226. PubMed ID: 28350084
[TBL] [Abstract][Full Text] [Related]
25. Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma.
Huang FY; Wong DK; Tsui VW; Seto WK; Mak LY; Cheung TT; Lai KK; Yuen MF
BMC Cancer; 2019 Aug; 19(1):789. PubMed ID: 31395065
[TBL] [Abstract][Full Text] [Related]
26. TP53 mutation detected in circulating exosomal DNA is associated with prognosis of patients with hepatocellular carcinoma.
Li Y; Wu J; Li E; Xiao Z; Lei J; Zhou F; Yin X; Hu D; Mao Y; Wu L; Wenjun L
Cancer Biol Ther; 2022 Dec; 23(1):439-445. PubMed ID: 35921289
[TBL] [Abstract][Full Text] [Related]
27. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma.
Wu X; Li J; Gassa A; Buchner D; Alakus H; Dong Q; Ren N; Liu M; Odenthal M; Stippel D; Bruns C; Zhao Y; Wahba R
Int J Biol Sci; 2020; 16(9):1551-1562. PubMed ID: 32226301
[TBL] [Abstract][Full Text] [Related]
28. Analysis of
Alvarez CS; Ortiz J; Bendfeldt-Avila G; Xie Y; Wang M; Wu D; Higson H; Lee E; Teshome K; Barnoya J; Kleiner DE; Groopman JD; Orozco R; McGlynn KA; Gharzouzi E; Dean M
Health Sci Rep; 2020 Jun; 3(2):e155. PubMed ID: 32382660
[TBL] [Abstract][Full Text] [Related]
29. Detection of TP53 gene mutation in blood of breast cancer patients based on circulating tumor DNA and its application in prognosis.
Lu Q; Wei L; Cai S; Zhang Z; Zhang L
Cell Mol Biol (Noisy-le-grand); 2023 Nov; 69(11):200-206. PubMed ID: 38015519
[TBL] [Abstract][Full Text] [Related]
30. Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.
Ikeda S; Lim JS; Kurzrock R
Mol Cancer Ther; 2018 May; 17(5):1114-1122. PubMed ID: 29483209
[TBL] [Abstract][Full Text] [Related]
31. Preoperative serum ctDNA predicts early hepatocellular carcinoma recurrence and response to systemic therapies.
Fu Y; Yang Z; Hu Z; Yang Z; Pan Y; Chen J; Wang J; Hu D; Zhou Z; Xu L; Chen M; Zhang Y
Hepatol Int; 2022 Aug; 16(4):868-878. PubMed ID: 35674872
[TBL] [Abstract][Full Text] [Related]
32. Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas.
Amaddeo G; Cao Q; Ladeiro Y; Imbeaud S; Nault JC; Jaoui D; Gaston Mathe Y; Laurent C; Laurent A; Bioulac-Sage P; Calderaro J; Zucman-Rossi J
Gut; 2015 May; 64(5):820-9. PubMed ID: 25021421
[TBL] [Abstract][Full Text] [Related]
33. The diagnostic and prognostic usage of circulating tumor DNA in operable hepatocellular carcinoma.
An Y; Guan Y; Xu Y; Han Y; Wu C; Bao C; Zhou B; Wang H; Zhang M; Liu W; Qiu L; Han Z; Chen Y; Xia X; Wang J; Liu Z; Huang W; Yi X; Huang J
Am J Transl Res; 2019; 11(10):6462-6474. PubMed ID: 31737198
[TBL] [Abstract][Full Text] [Related]
34. Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China.
Yi Z; Ma F; Rong G; Guan Y; Li C; Xu B
Cancer Commun (Lond); 2020 Jun; 40(6):260-269. PubMed ID: 32436611
[TBL] [Abstract][Full Text] [Related]
35. Association between HBX status, aflatoxin-induced R249S TP53 mutation and risk of hepatocellular carcinoma in a case-control study from Thailand.
Ortiz-Cuaran S; Villar S; Gouas D; Ferro G; Plymoth A; Khuhaprema T; Kalalak A; Sangrajrang S; Friesen MD; Groopman JD; Hainaut P
Cancer Lett; 2013 Apr; 331(1):46-51. PubMed ID: 23200676
[TBL] [Abstract][Full Text] [Related]
36. Applications of molecular barcode sequencing for the detection of low-frequency variants in circulating tumour DNA from hepatocellular carcinoma.
Lee HW; Kim E; Cho KJ; Park HJ; Seo J; Lee H; Baek E; Choi JR; Han KH; Lee ST; Park JY
Liver Int; 2022 Oct; 42(10):2317-2326. PubMed ID: 35776657
[TBL] [Abstract][Full Text] [Related]
37. Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib.
Fujii Y; Ono A; Hayes CN; Aikata H; Yamauchi M; Uchikawa S; Kodama K; Teraoka Y; Fujino H; Nakahara T; Murakami E; Miki D; Okamoto W; Kawaoka T; Tsuge M; Imamura M; Chayama K
J Exp Clin Cancer Res; 2021 Jun; 40(1):215. PubMed ID: 34174931
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment.
Sogbe M; Bilbao I; Marchese FP; Zazpe J; De Vito A; Pozuelo M; D'Avola D; Iñarrairaegui M; Berasain C; Arechederra M; Argemi J; Sangro B
Clin Mol Hepatol; 2024 Apr; 30(2):177-190. PubMed ID: 38163441
[TBL] [Abstract][Full Text] [Related]
39. Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with
Lim HY; Merle P; Weiss KH; Yau T; Ross P; Mazzaferro V; Blanc JF; Ma YT; Yen CJ; Kocsis J; Choo SP; Sukeepaisarnjaroen W; Gérolami R; Dufour JF; Gane EJ; Ryoo BY; Peck-Radosavljevic M; Dao T; Yeo W; Lamlertthon W; Thongsawat S; Teufel M; Roth K; Reis D; Childs BH; Krissel H; Llovet JM
Clin Cancer Res; 2018 Oct; 24(19):4650-4661. PubMed ID: 29950351
[No Abstract] [Full Text] [Related]
40. Circulating cell-free DNA of methylated insulin-like growth factor-binding protein 7 predicts a poor prognosis in hepatitis B virus-associated hepatocellular carcinoma after hepatectomy.
Li F; Qiao CY; Gao S; Fan YC; Chen LY; Wang K
Free Radic Res; 2018 Apr; 52(4):455-464. PubMed ID: 29463155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
